Table of Content

1. Executive Summary

     
    Executive Summary
        Key Findings—Analysis of Companies to Action
        Key Findings—Analysis of Companies to Action (continued)
        Scope and Segmentation
        Key Questions Addressed in this Study

 2. Companies to Action Overview

     
    Companies to Action Overview
        Companies to Action Value Creators
        Opportunities and Threats

 3. Cell Therapy Market Overview

     
    Cell Therapy Market Overview
        Market Definitions
        Market Segmentation
        Cell Therapy Value Chain
        Vendor Ecosystem
        Impact of Key Market Influencers
        Top 3 Trends and Vendor Strategies
        Key Market Participants Aligned with Top 3 Trends
        Cell Therapy—Vendor Landscape

 4. C2A Profiles—Tier I

     
    C2A Profiles—Tier I
        Juno Therapeutics—Overview
        Juno Therapeutics—Technology Platforms
        Juno Therapeutics—Major Partnerships and Agreements
        bluebird bio—Business Overview
        bluebird bio—Technology Platform
        bluebird bio—Major Partnerships and Agreements
        Kite Pharma—Overview
        Kite Pharma—Key Technology/ Product/Services
        Kite Pharma—Case Example and Recent Developments
        Adaptimmune—Overview
        Adaptimmune—Technology Platforms
        Adaptimmune—Case Example and Recent Developments
        Oxford BioMedica—Overview
        Oxford BioMedica—Technology Platform
        Oxford BioMedica—Case Example and Recent Developments
        JCR Pharmaceuticals—Overview
        JCR Pharmaceuticals—Technology Platforms
        JCR Pharmaceuticals—Case Example and Recent Developments

 5. C2A Profiles—Tier II

     
    C2A Profiles—Tier II
        Sangamo Therapeutics—Company Overview
        Sangamo Therapeutics—Value Proposition
        DiscGenics—Company Overview
        DiscGenics—Value Proposition
        TiGenix—Company Overview
        TiGenix—Value Proposition
        Bone Therapeutics—Company Overview
        Bone Therapeutics—Value Proposition
        Cell Medica—Company Overview
        Cell Medica—Value Proposition
        Mesoblast—Company Overview
        Mesoblast—Value Proposition
        Cynata Therapeutics—Company Overview
        Cynata Therapeutics—Value Proposition
        Medipost—Company Overview
        Medipost—Value Proposition
        Anterogen—Company Overview
        Anterogen—Value Proposition
        Pharmicell—Company Overview
        Pharmicell—Value Proposition

 6. C2A Profiles—Tier III

     
    C2A Profiles—Tier III
        Short Profiles of Digital Pathology Companies
        Short Profiles of Digital Pathology Companies (continued)
        Short Profiles of Digital Pathology Companies (continued)
        Short Profiles of Digital Pathology Companies (continued)

 7. Growth Opportunities and Companies to Action

     
    Growth Opportunities and Companies to Action
        Transformation in the Industry Ecosystem
        Five Major Growth Opportunities
        Strategic Imperatives for Growth

 8. The Last Word

     
    The Last Word
        Conclusion—Key Takeaways
        Legal Disclaimer

 9. Appendix

     
    Appendix
        Abbreviation List
        List of Exhibits
        List of Exhibits (continued)